Vimarsana
Biggest News Aggregation in the World

Methylmalonic Acidemia News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Methylmalonic Acidemia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Methylmalonic Acidemia Today - Breaking & Trending Today

Fourth Generation of Sicilian Farmers Celebrate Local Cultivars - Vimarsana News

Fourth Generation of Sicilian Farmers Celebrate Local Cultivars

In southeastern Sicily, the producers behind Vernèra share a sense of social responsibility and environmental sustainability.

Why Moderna (MRNA) Shares Are Trading Lower Today - Moderna (NASDAQ:MRNA) - Vimarsana News

Why Moderna (MRNA) Shares Are Trading Lower Today - Moderna (NASDAQ:MRNA)

William Blair initiated coverage on Moderna Inc (NASDAQ: MRNA) with a Market Perform rati

Moderna's seven priorities for 2023: from AI to cancer vaccines - Vimarsana News

Moderna's seven priorities for 2023: from AI to cancer vaccines

MRNA pioneer Moderna wants to grow and thrive past its initial COVID-19 vaccine success. “To continue to build the best version of Moderna, we have established seven priorities for 2023,” says CEO Stephane Bancel: as the company outlines goals that range from embracing AI to a 'bold campaign' of cancer vaccine studies.

BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update - Vimarsana News

BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update

03.11.2022 - - Reported positive preclinical data for its next-generation KRASG12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3Kα:RAS breaker mechanism in late lead optimization - Reported positive updated 12-month Phase 2 data ...

LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Vimarsana News

LogicBio Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage genetic medicine company, today reported financial results for the second quarter...